Therapeutical effects of PPAR agonists assessed by biomarker modulation

References

• Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflammation Research 2000b; 49: 497–505
   PubMed Web of Science ®Google Scholar
• Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall. Z. Kardiologia 2001b; 90: 125–132
   PubMedGoogle Scholar
• Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications. International Journal of Obesity Related Metabolic Disorders 2003; 27(Suppl 3)S41–S45
   Google Scholar
• Chinetti G, Gbaguidi GF, Griglio S, Mallat Z, Antonucci H, Póulain P, Chapman J, Fruchart JC, Tedgui A, Nadib-Fruchart J, Staels B. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000a; 101: 2411–2417
   PubMed Web of Science ®Google Scholar
• Chinetti G, Lestavel S, Bocher V, Remaley A, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, et al. PPARα and PPARγ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Medicine 2001a; 7: 53–58
   PubMed Web of Science ®Google Scholar
• Despres JP, Lemieux I, Pascot A, Almeras N, Dumont N, Nadeau A, Bergeron J, Prud'Homme D. Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome. Arteriosclerosis Thrombosis and Vascular Biology 2003; 23: 702–703
   PubMed Web of Science ®Google Scholar
• Faveeuw C, Fougeray S, Angeli V, Fontaine J, Chinetti S, Gosset P, Delerive P, Maliszewski C, Capron A, Staels B, et al. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-12 production in murine dendritic cells. FEBS Letters 2000; 486: 261–266
   PubMed Web of Science ®Google Scholar
• Gervois P, Kleemann R, Pilon A, Percevault F, Koenig F, Staels B, Kooistra T. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. Journal of Biological Chemistry 2004; 279: 16154–16160
   PubMed Web of Science ®Google Scholar
• Gervois P, Vu-Dac N, Kleemann R, Kockx M, Dubois G, Laine B, Kosykh V, Fruchart JC, Kooistra T, Staels B. Negative regulation of human fibrinogen gene expression by PPAR{alpha} agonists via inhibition of C/EBPbeta. Journal of Biological Chemistry 2001; 276: 33471–33477
   PubMed Web of Science ®Google Scholar
• Gosset P, Charbonnier AS, Delerive P, Fontaine J, Staels B, Pastel J, Tonnel AB, Trottein F. Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. European Journal of Immunology 2001; 31: 2857–2865
   PubMed Web of Science ®Google Scholar
• Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679–684
   PubMed Web of Science ®Google Scholar
• Hirano T, Yoshino G, Kazumi T. Troglitazone and small low-density lipoprotein in type 2 diabetes. Annals of Internal Medicine 1998; 129: 162–163
   Google Scholar
• Jonkers IJ, Mohrschladt MF, Westendorp RG, van der Laarse A, Smelt AH. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. American Journal of Medicine 2002; 112: 275–280
   PubMed Web of Science ®Google Scholar
• Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NF{kappa}B ∼C/EBP- {beta} complex formation. Blood 2002; 101: 545–551
   Google Scholar
• Kowalski J, Okopien B, Madej A, Belowski D, Zielinski M, Kowalski J, Herman ZS. Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia. International Journal of Clinical Pharmacology Therapy 2003; 41: 241–247
   PubMed Web of Science ®Google Scholar
• Kwak BR, Myit S, Mulhaupt F, Veillard N, Ruter N, Roosnek E, Mach F. PPARgamma but not PPARalpha ligands are potent repressors of major histocompatibilty complex class II induction in atheroma-associated cells. Circulation Research 2002; 90: 356–362
   Google Scholar
• Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JP. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 2004; 27: 41–46
   PubMed Web of Science ®Google Scholar
• Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, Szygula B, Kalina Z, Herman ZS. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. International Journal of Clinical Pharmacology Therapy 1998; 36: 345–349
   PubMed Web of Science ®Google Scholar
• Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Scharnagl H, Hombach V, Koenig W. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arteriosclerosis Thrombosis and Vascular Biology 2003a; 23: 283–288
   PubMed Web of Science ®Google Scholar
• Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Maerz W, Hombach V, Koenig W. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003b; 107: 1954–1957
   PubMed Web of Science ®Google Scholar
• Marx N, Kehrle B, Kohlhammer K, Grub M, Koenig W, Hombach V, Libby P, Putzky J. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circulation Research 2002; 90: 703–710
   PubMed Web of Science ®Google Scholar
• Meier C, Chicheportiche R, Juge-Aubry C, Dreyer M, Dayer J. Regulation of the interleukin-1 receptor antagonist in THP-1 cells by ligands of the peroxisome proliferator-activated receptor gamma. Cytokines 2002; 18: 320–328
   Google Scholar
• Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. Journal of Clinical Endocrinology Metabolism 2004; 89: 2728–2735
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ushiyama C, Shimada N, Hayashi K, Ebihara I, Koide H. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. Journal of Diabetes Complications 2000; 14: 250–254
   PubMed Web of Science ®Google Scholar
• Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000; 43: 278–284
   PubMed Web of Science ®Google Scholar
• Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. Journal of the American College of Cardiology 2003; 42: 1757–1763
   PubMed Web of Science ®Google Scholar
• Sidhu JS, Cowan D, Tooze JA, Kaski JC. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. American Heart Journal 2004; 147: e25
   PubMedGoogle Scholar
• Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998a; 98: 2088–2093
   PubMed Web of Science ®Google Scholar
• Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 1998b; 393: 790–793
   PubMed Web of Science ®Google Scholar
• Sunayama S, Watanabe Y, Ohmura H, Sawano M, Shimada K, Mokuno H, Daida H, Yamaguchi H. Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. Atherosclerosis 1999; 146: 187–193
   PubMed Web of Science ®Google Scholar
• Tack CJ, Smits P, Demacker PN, Stalenhoef AF. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 1998; 21: 796–799
   PubMed Web of Science ®Google Scholar
• Vu-Dac N, Gervois P, Jakel H, Nowak M, Bauge M, Dehondt H, Staels B, Pennacchio LA, Rubin EM, Fruchart-Nájib J, Fruchart JC. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. Journal of Biological Chemistry 2003; 278: 17982–17985
   PubMed Web of Science ®Google Scholar
• Yan XY, Wang LH, Chen T, Hodge DR, Resau JH, DaSilva L, Farrar WL. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. Journal of Biological Chemistry 2000; 275: 4541–4544
   Google Scholar